Epoch Biodesign develops enzymatic processes that depolymerize pre- and post-consumer plastic and textile waste into monomers, recovering more than 90% of desired monomers through a cascade of enzyme treatments. The company sources industrial enzymes rather than using live microbes and captures dyes as a separate byproduct to be treated independently. Its current commercial focus is nylon 6,6, a high-strength synthetic fiber used in apparel, airbags, carpets and other applications, with plans to adapt the platform to other plastics over time. Epoch is building a demonstration-scale facility near Imperial College London and plans a commercial-scale plant expected online in 2028 with capacity targeted at 20,000 metric tons per year of monomer. The company was founded and is led by CEO Jacob Nathan and has secured strategic investor support including Lululemon through its recent $12 million funding round.

Total raised

$42M

Funding rounds

4

Latest round

Equity

Latest activity

Mar 2026